Jhon Fredy Bello Cordero*, Urbano David Benitez Russo, Fernan Andres Torres Hernandez, Jesus Miguel Moreno Martinez, Mayerly del Carmen Mercado Oliva, Daniel Nicolas Pinilla Lopez, Miguel Angel Iglesias Herrera, Jhoyner Alberto Jimenez Filigrana
The disease caused by a B-coronavirus, an RNA virus, had its beginnings in 2019 in Wuhan - China where a series of cases of pneumonia caused by this agent were identified, after sequencing the nucleic acid of the epithelial cells of the lower respiratory tract of 4 patients with confirmed pneumonia of unknown cause by realtime reverse transcription PCR at Beijing Hospital, a new beta coronavirus 2019-nCoV, which was later named SARS-CoV-2, was found. Currently there are only maintenance therapies and symptom management, since there are no exact therapies for the management of severe SarsCoV2 infection, antiviral drugs and other drugs used to manage the infection such as acyclovir, panciclovir, chloroquine are used , ganciclovir, remdesivir, nitazoxadine, corticosteroids among other medications currently used for symptom management- The use of neutralizing antibody therapy may alter the course of infection in an infected host, support viral shedding, or protect uninfected hosts exposed to the virus, therefore, this antibody, used alone or in combination, has the potential to prevent and treat COVID-19 and possibly other emerging human diseases caused by the subgenus Sarbecovirus, in addition to being a low-toxic drug and safe. Its use in these patients.
English 
Spanish 
Chinese 
Russian 
German 
Japanese 
Portuguese 
Hindi